Pacira BioSciences, Inc. (PCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.46B
Last updated: Nov 17, 2026 at 3:04 AM ET
Pacira BioSciences, Inc. (PCRX) Financials: Revenue, Profit and Cash Flow
Pacira BioSciences reported revenue of $726.41M for the fiscal year ended Dec 31, 2025, up 3.6% from the year before. That year, net income was $7.03M with a net margin of 1.0%, operating cash flow was $151.99M and free cash flow was $136.66M. The quarter ended Sep 30, 2026 had revenue of $176.65M and net income of $28.52M.
Revenue and Margins
The operating margin was 2.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $276.37M, a compound annual rate of 11.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $726.41M | +3.6% | 79.4% | 2.6% | 1.0% |
| Dec 2024 | $700.97M | +3.9% | 75.7% | -10.5% | -14.2% |
| Dec 2023 | $674.98M | -49.4% | 72.6% | 13.0% | 6.2% |
| Dec 2022 | $1.33B | +146.3% | 85.1% | 4.5% | 2.4% |
| Dec 2021 | $541.53M | +26.0% | 74.1% | 16.6% | 7.8% |
| Dec 2020 | $429.65M | +2.0% | 72.7% | 10.8% | 33.9% |
| Dec 2019 | $421.03M | +24.8% | 74.7% | 2.5% | -2.6% |
| Dec 2018 | $337.28M | +17.7% | 74.3% | 4.7% | -0.1% |
| Dec 2017 | $286.63M | +3.7% | 69.3% | -8.7% | -14.9% |
| Dec 2016 | $276.37M | N/A | 60.2% | -11.6% | -13.7% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 425.2% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726.41M | $700.97M | $674.98M | $1.33B | $541.53M | $429.65M | $421.03M | $337.28M | $286.63M | $276.37M |
| Cost of revenue | $149.75M | $170.43M | $184.67M | $199.29M | $140.25M | $117.33M | $106.71M | $86.84M | $87.92M | $110.10M |
| Gross profit | $576.66M | $530.54M | $490.31M | $1.13B | $401.28M | $312.32M | $314.31M | $250.43M | $198.72M | $166.27M |
| Research and development | $117.31M | $81.58M | $76.26M | $84.80M | $55.55M | $59.42M | $72.12M | $55.69M | $57.29M | $45.68M |
| Operating income | $19.19M | -$73.37M | $87.67M | $60.02M | $89.92M | $46.35M | $10.48M | $15.91M | -$24.94M | -$32.02M |
| Net income | $7.03M | -$99.56M | $41.95M | $31.82M | $41.98M | $145.52M | -$11.02M | -$471.00K | -$42.61M | -$37.95M |
| EBITDA | $101.66M | $842.00K | $162.24M | $100.72M | $141.71M | $87.36M | $40.53M | $40.99M | $734.00K | -$14.62M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $176.65M | $192.40M | $177.38M | $196.87M | $179.52M | $181.10M | $168.92M | $187.25M | $168.57M | $178.02M | $167.12M | $181.24M |
| Gross profit | $139.42M | $148.24M | $140.96M | $156.57M | $145.24M | $140.23M | $134.62M | $147.37M | $129.71M | $133.76M | $119.70M | $133.55M |
| Operating income | $22.27M | $4.27M | $6.90M | $2.34M | $6.36M | $8.50M | $1.99M | $24.70M | -$139.53M | $28.24M | $13.21M | $33.17M |
| Net income | $28.52M | $4.65M | $2.92M | $1.64M | $5.43M | -$4.85M | $4.81M | $16.04M | -$143.47M | $18.89M | $8.98M | $24.87M |
Balance Sheet
As of Dec 2025, total debt of $382.03M exceeded cash and equivalents by $223.48M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B | $831.07M | $689.35M | $628.37M | $391.47M |
| Current assets | $547.97M | $745.13M | $509.99M | $498.33M | $866.05M | $651.62M | $408.56M | $477.97M | $391.11M | $243.09M |
| Cash and equivalents | $158.54M | $276.77M | $153.30M | $104.14M | $585.58M | $99.96M | $78.23M | $132.53M | $54.13M | $35.94M |
| Total liabilities | $571.81M | $775.17M | $704.26M | $906.19M | $1.34B | $654.83M | $476.12M | $368.13M | $348.89M | $172.49M |
| Short-term debt | $9.84M | $201.78M | $8.64M | $33.65M | $374.70M | $149.65M | $0 | $338.00K | $324.00K | $0 |
| Long-term debt | $372.19M | $383.55M | $513.80M | $655.82M | $674.53M | $313.03M | $306.05M | $290.59M | $276.17M | $108.74M |
| Shareholder equity | $693.11M | $778.35M | $870.13M | $775.01M | $730.41M | $619.69M | $354.94M | $321.23M | $279.48M | $218.98M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.20B | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B | $1.55B | $1.52B | $1.65B | $1.58B | $1.57B |
| Total liabilities | $490.32M | $572.00M | $554.64M | $571.81M | $570.36M | $779.50M | $788.13M | $775.17M | $772.11M | $767.54M | $691.16M | $704.26M |
| Cash and equivalents | $246.96M | $205.88M | $144.31M | $158.54M | $147.59M | $300.48M | $283.61M | $276.77M | $245.97M | $247.05M | $184.05M | $153.30M |
| Shareholder equity | $712.32M | $671.98M | $653.89M | $693.11M | $727.21M | $757.77M | $798.54M | $778.35M | $749.58M | $879.28M | $892.16M | $870.13M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 89.9% of operating cash flow. Share repurchases came to 110.1% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $151.99M | $189.39M | $154.65M | $145.27M | $125.72M | $77.03M | $70.52M | $48.87M | $17.79M | $33.45M |
| Capital expenditures | $15.33M | $10.64M | $15.16M | $30.08M | $45.87M | $37.80M | $10.16M | $14.51M | $19.27M | $24.71M |
| Free cash flow | $136.66M | $178.75M | $139.49M | $115.20M | $79.85M | $39.23M | $60.36M | $34.36M | -$1.48M | $8.74M |
| Dividends paid | N/A | N/A | $2.81M | N/A | $2.67M | $1.62M | $4.32M | N/A | $0 | $0 |
| Share repurchases | $150.51M | $34.35M | $1.16M | $1.18M | $4.55M | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $99.48M | -$83.28M | $77.54M | -$225.19M | -$20.79M | -$277.61M | -$128.49M | $20.58M | -$223.76M | -$61.75M |
| Financing cash flow | -$369.63M | $17.36M | -$183.03M | -$401.53M | $380.69M | $222.30M | $3.67M | $8.95M | $224.16M | $7.26M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $50.07M | $57.46M | $25.68M | $43.69M | $60.83M | $12.01M | $35.46M | $33.13M | $53.92M | $53.24M | $49.10M | $47.58M |
| Capital expenditures | $3.63M | $1.34M | $2.72M | $218.00K | $3.87M | $2.70M | $8.55M | $2.12M | $4.09M | $1.59M | $2.84M | $1.80M |
| Free cash flow | $46.45M | $56.12M | $22.96M | $43.47M | $56.96M | $9.31M | $26.91M | $31.01M | $49.83M | $51.65M | $46.27M | $45.79M |
Frequently Asked Questions About PCRX
What is Pacira BioSciences' annual revenue?
Pacira BioSciences reported revenue of $726.41M for the fiscal year ended Dec 31, 2025.
How fast is Pacira BioSciences' revenue growing?
Revenue was up 3.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -18.3%.
Is Pacira BioSciences profitable?
Yes. Pacira BioSciences reported net income of $7.03M for the fiscal year ended Dec 31, 2025, with a net margin of 1.0%.
How much free cash flow does PCRX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $151.99M minus capital expenditures of $15.33M produced free cash flow of $136.66M.
How much debt does Pacira BioSciences have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $372.19M, short-term debt of $9.84M and cash and equivalents of $158.54M.
PCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors